Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
US11674172B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11674172-B2 |
| Application number | US-202217830354-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 2, 2022 |
| Priority date | Feb 12, 2018 |
| Publication date | Jun 13, 2023 |
| Grant date | Jun 13, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention relates to a piRNA-54265 detection kit used for early screening, diagnosis, efficacy monitoring and/or prognostic evaluation of colorectal cancer. The detection kit includes a primers combination, including a primer pair and a probe for specifically detecting piRNA-54265; the primer pair is a piRNA-54265 stem-loop PCR primer pair, or a piRNA-54265 PolyA tailed PCR primer pair; the primer pair includes a forward primer and a reverse primer.
Opening claim text (preview).
What is claimed is: 1. A composition comprising a primer pair and probe for specifically detecting piRNA-54265, wherein said primer pair is selected from: (a) a first primer pair for amplifying piRNA-54265 containing a stem loop comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO: 26 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO: 9 and (b) a second primer pair for amplifying a poly-A tailed piRNA-54265 comprising a forward primer consisting of the nucleotide sequence of SEQ ID NO: 26 and a reverse primer consisting of the nucleotide sequence of SEQ ID NO: 22; and wherein said probe consists of the nucleotide sequence of SEQ ID NO: 27. 2. The composition according to claim 1 , further comprising a primer for reverse transcription. 3. The composition according to claim 2 , wherein the primer for reverse transcription is for reverse transcribing a piRNA-54265 containing a stem loop and wherein the primer for reverse transcription consists of the nucleotide sequence of SEQ ID NO: 2. 4. A piRNA-54265 detection kit, comprising the composition according to claim 3 . 5. The composition according to claim 2 , wherein the primer for reverse transcription is for reverse transcribing a poly-A tailed piRNA-54265 and wherein the primer for reverse transcription consists of one of the nucleotide sequences selected from SEQ ID NOs: 3-5. 6. A piRNA-54265 detection kit, comprising the composition according to claim 5 . 7. A piRNA-54265 detection kit, comprising the composition according to claim 2 . 8. A piRNA-54265 detection kit, comprising the composition according to claim 1 .
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)} · CPC title
Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title
for cancer (immunoassay for cancer G01N33/575) · CPC title
for detection of mutation or polymorphism · CPC title
targeting other non-coding nucleic acids, e.g. antagomirs · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.